Please	type	a plus	algn	(+) inside	this box	+
1-10090	iypo	a pico	aim.	(-)	440 000	

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for	form 1449A/PTC)			Complete if Known
				Application Number	09/194,356
	MATION			Filing Date	September 2, 1999
STATE	MENT B	Y APP	LICANT	First Named Inventor	Dario NERI et al.
				Group Art Unit	1642-1643
(us	se as many she	ets as nec	essary)	Examiner Name	Alana M. Harris
Sheet	1	of	1	Attorney Docket Number	ELLIS-0003

		THE REPORT OF THE PROPERTY OF	
Examiner Initials *	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
amh		EPSTEIN, Jay S., "FDA Regulation of HIV-Related Tests and Procedures," Aids Testing: A comprehensive Guide to Technical, Medical, Social, Legal, and Management Issues, Eds. Schochetman and George, pp. 52-61, Springer-Verlag, New York. 1994	
	2	KORVER et al., "Measurement of Primary In Vivo IgM- and IgG-Antibody Response to KLH in Humans: Implications of Pre-Immune IgM Binding in Antigen-Specific ELISA," Journal of Immunological Methods, 1984, pp. 241-251, vol. 74.	
	3	WEIR, C. et al., "An Immunoglobulin G1 Monoclonal Antibody Highly Specific to the Wall of Cryptosporidium Occysts," Clinical and Diagnostic Laboratory Immunology, Sept. 2000, p. 745-750, Vol. 7, No. 5.	
\/	4	NOZAWA, Shiro, et al., "HMMC-1: A Humanized Monoclonal Antibody With Therapeutic Potential Against Müllerian Duct-Related Carcinomas," Clinical Cancer Research, October 15, 2004, pp. 7071-7078, vol. 10.	
V-	5	23 slide, power-point of Dr. Zardi (February 2007).	
			<u>L</u>

Examiner Signature	amtarlis	Date Considered	14 May	1 2007
	<u></u>			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique cliation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



ontrol number.

Sheet 2

Substitute for form 1449B/PTO

COPY OF PAPERS ORIGINALLY FILED

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE fied to respond to a collection of information unless it contains a valid OMB

Under the Paperwork Reduction Act of 1995, no persons a

Complete if Known 09/154,356 September 2, 1999 **Application Number** INFORMATION DISCLOSURE Filing Date AUG 3 2002 Dario Neri, et al First Named Inventor STATEMENT BY APPLICANT Group Art Unit 1643 (use as many sheets as necessary) **Examiner Name** TECH CENTER 1600/2900 of 2 Attorney Docket Number 515-4132

Property of the property of th	Include name of the author (in CAPITAL LETTERS), little of the article (when appropriate), tille of the litem (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-lesue number(s), publisher, city and/or country where number(s), publisher, city and/or country where number(s), volume-lesue number(s), publisher, city and/or country where number(s), volume-lesue number(s), page(s), volume-lesue numbe
Property of the property of th	ATRIZIA CASTELLANI, et al "The Fibronectin Isoform Containing the ED-B Oncofetal Imain: A Marker of Angiogenesis" 1994, Vol 59, pp 612-618 Publication of the International Imain: A Marker of Angiogenesis 1994, Vol 59, pp 612-618 Publication of the International Imain: Against Cancer Genoa, Italy UCIANO ZARDI, et al "Transformed Human Cells Produce A New Fibronection Isoform By Eferential Alternative Splicing of a Previously unobserved Exon" 1987, Vol.6 No. 8, pp2337-2342, et Embo Journal IRL Press Limited Oxford, England IRBARA CARNEMOLLA, et al "The Inclusion of the Type III Repeat ED_R in the Fibronectin
Do Un ELL Pre The	omain: A Marker of Angiogenesis" 1994, Vol 59, pp 612-618 Publication of the International nion Against Cancer Genoa, Italy UCIANO ZARDI, et al "Transformed Human Cells Produce A New Fibronection Isoform By efferential Alternative Splicing of a Previously unobserved Exon" 1987, Vol.6 No. 8, pp2337-2342, e Embo Journal IRL Press Limited Oxford, England RBARA CARNEMOLLA, et al "The Inclusion of the Type III Repeat ED_R in the Fibronectin
Pre Th	UCIANO ZARDI, et al "Transformed Human Cells Produce A New Fibronection Isoform By eferential Alternative Splicing of a Previously unobserved Exon" 1987, Vol.6 No. 8, pp2337-2342, e Embo Journal IRL Press Limited Oxford, England RBARA CARNEMOLLA, et al "The Inclusion of the Type III Repeat ED_R in the Fibronectin
BA	ARBARA CARNEMOLLA, et al "The Inclusion of the Type III Repeat ED_R in the Fibronectin
I IN NO	olecule Generates Conformational Modifications that Unmask a Cryptic Sequence" 1992, Vol.267 b. 34, pp.24689-24692 The Journal of Biological Chemistry Printed in U.S.A.
BA On of	ARBARA CARNEMOLLA, et al "Phage Antibodies with Pan-Species Recognition of the neofoetal Angiogenesis Marker Fibronectin ED-B Domain" 1996, Vol.68, pp.397-405 Publication the International Union Against Cancer Genoa. Italy
I h. N Ek	evated Levels of Both Extra Domain B(+) and B(-) Fibronection in Osteoarthritic Canine artilage" 1994, Vol.14 pp.623-633 Gustav Fischer Verlag, Stuttgart-Jena New York
	·
	·

Signature Considered Whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.